Skip to content

STEM CELLS FOR OVARIAN REJUVENATION (The SCORE trial)

OVARIAN REJUVENATION WITH AUTOLOGOUS ADIPOSE DERIVED STEM CELL THERAPY

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
PACTR
Registry ID
PACTR202007828853091
Enrollment
30
Registered
2020-07-06
Start date
2020-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female

Interventions

Autologous adipose derived stem cell insertion into ovary
Placebo injection into ovary

Sponsors

Oxford road Day clinic
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - Infertile women with either premature ovarian failure diagnosed clinically and biochemically - Infertile women with very low ovarian reserves diagnosed both biochemically with low AMH and radiologically with low AFC - Eligible women must consent to partake in the study

Exclusion criteria

Exclusion criteria: - A history of current or previous malignancy - Any other co-existing cause of infertility in the couple (male or female factors) - The inability to visualize the ovaries on transvaginal ultrasound - Age >42 years - Smoker

Design outcomes

Primary

MeasureTime frame
1)hormonal biomarkers indicating recovery of ovarian function; (a decline in FSH and a rise in AMH) 2)resumption of menstruation in amenorrheic women 3)response to ovarian stimulation, oocyte quantity obtained, embryo grading, euploidy rates and pregnancy outcome

Secondary

MeasureTime frame
1) to determine the optimal concentration of stem cells to be used 2) to determine the effects of ovarian perfusion on stem cell grafting 3) to determine the ideal patient candidate who is likely to benefit from stem cell therapy.

Countries

South Africa

Contacts

Public ContactJamila Kathoon Adam

Supervisor

adamjk@dut.ac.za+27827860682

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026